Trastuzumab immunogenicity development in patients’ sera and in laboratory animals

BMC Immunology

Table 3 Anti-trastuzumab Ab levels developed in 32 patien’s serum samples and determined at two different points during trastuzumab treatment course

Sample code	No. of administered doses before 1st assay point	1st assay point titer			No. of administered doses before 2nd assay point	2nd assay point titer
		Value	±SD	*Percentage of positive samples		Value	±SD	**Percentage of positive samples
T2–65	1	1.36	0.01	71.43%	12	ND		28.13%
T2–66		1.94	0.02		10	1.65	0.04
T2–66		1.94	0.02		12	ND
T2–67		ND			10	ND
T2–68		1.61	0.02		16	ND
T2–69		ND			10	ND
T2–70		3.1	0.01		7	ND
T2–71		2.77	0.05		10	1.37	0.07
T2–72	2	ND		80%	12	ND
T2–73		1.78	0.06		14	2.25	0.01
T2–74		1.56	0.09		12	1.02	0.03
T2–75		3.07	0.05		14	2.4	0.04
T2–76		2.93	0.1		10	1.01	0.04
T2–77	3	ND		0%	8	ND
T2–77		ND			15	ND
T2–78		ND			17	ND
T2–79		ND			15	ND
T2–80	4	ND		33.33%	6	ND
T2–81		2.24	0.02		14	ND
T2–82		0.85	0.1		12	ND
T2–83		ND			16	ND
T2–84		ND			14	ND
T2–85		1.13	0.01		14	1.33	0.001
T2–86	6	ND		25%	13	ND
T2–87		ND			15	ND
T2–88		2.43	0.01		13	ND
T2–89		ND			14	ND
T2–90	7	2.63	0.16	67%	13	1.18	0.03
T2–91		ND			16	ND
T2–92		4.64	0.03		17	1.67	0.05
T2–93	8	ND		50%	17	ND
T2–94		0.85	0.01		15	ND
T2–95		1.29	0.08		16	ND
T2–96		1.95	0.06		16	ND

*Percentage of positive samples was calculated from samples that gave titers ≥1 relative to the number of tested samples of patients administered the same number of doses
**Percentage of positive samples was calculated from samples that gave titers ≥1 relative to the total number of samples in 2nd assay point

ISSN: 1471-2172